- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01118299
AMPLATZER Cardiac Plug Clinical Trial
Amplatzer Cardiac Plug Clinical Trial
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Stati Uniti, 90017
- Good Samaritan Hospital
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- University of Colorado Denver
-
Littleton, Colorado, Stati Uniti, 80120
- South Denver Cardiology Associates
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory Midtown Hospital and Emory University Hospital
-
Atlanta, Georgia, Stati Uniti
- St. Joseph's Hospital and Research Institute
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa Hospitals & Clinics
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40506
- University of Kentucky
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Spectrum Health
-
Southfield, Michigan, Stati Uniti, 48075
- Providence Hospital
-
-
Minnesota
-
Saint Cloud, Minnesota, Stati Uniti, 56303
- St. Cloud Hospital/CentraCare Heart and Vascular Clinic
-
Saint Paul, Minnesota, Stati Uniti, 55102
- HealthEast St. Joseph's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- University of Pennsylvania
-
York, Pennsylvania, Stati Uniti, 17405
- York Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29401
- Roper Hospital/PMG Research of Charleston
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Memorial Hermann Hospital
-
-
Wisconsin
-
Wausau, Wisconsin, Stati Uniti, 54401
- Aspirus Heart & Vascular Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation
- Subject must be ≥18 years of age
- Subject must be on warfarin or dabigatran therapy
- Subject must be eligible for long term warfarin or dabigatran therapy
- Subject must have a CHADS(2) score of 2 or greater
Summary of Exclusion Criteria:
- Subject who requires warfarin or dabigatran for a condition other than AF
- Subject who is on clopidogrel or another P2Y12 platelet inhibitor such as prasugrel or ticagrelor
- Subject who has an absolute or relative contraindication to aspirin, or warfarin and dabigatran
- Subject with a New York Heart Association (NYHA) classification equal to IV
- Subject with an implanted or surgical repair atrial septal defect (ASD) device or patent foramen ovale (PFO) device
- Subject with aortic or mitral valve regurgitation of grade 2+ or greater
- Subject with left ventricular ejection fraction (LVEF) ≤30
- Subject with mitral or aortic prosthetic valve
- Subject with a history of hemorrhagic or aneurysmal stroke
- Subject with a history of previous radio frequency (RF) ablation for atrial fibrillation
- Subject with a body mass index (BMI) ≥40
- Subject with a history of acute or recent MI, or unstable angina, or coronary artery bypass graft surgery (within 6 months)
- Subject who is on aspirin dose therapy greater than 81mg/day at time of enrollment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Device
AMPLATZER Cardiac Plug
|
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
|
Comparatore attivo: Optimal Medical Therapy (control)
Warfarin Dabigatran
|
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Acute Safety - Procedure Related SAEs From Randomization Through Discharge For Device Arm Only
Lasso di tempo: From Randomization to Discharge Visit
|
An analysis comparing the rate of procedure related serious adverse events that occur in the device arm to a performance goal determined from literature reported rates for similar procedural techniques. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm below. The secondary endpoint analysis requirement was removed from the protocol. |
From Randomization to Discharge Visit
|
Long-term Safety - Device Arm Only
Lasso di tempo: Randomization to 2 year follow-up
|
All-Cause Mortality and Major Bleeds Through 2 years in device arm subjects only. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol. |
Randomization to 2 year follow-up
|
Effectiveness Endpoint - Device Arm Only
Lasso di tempo: Randomization through 2 year follow up
|
Occurrence of ischemic stroke and peripheral thromboembolism in the device arm. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol. |
Randomization through 2 year follow up
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CL00921
Informazioni su farmaci e dispositivi, documenti di studio
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su AMPLATZER Cardiac Plug
-
Zhen Jun WangPeking University Third Hospital; Beijing Luhe Hospital; Beijing Shuyi Hospital; The... e altri collaboratoriSconosciutoFistola anale | Spina LIFT | Tasso di guarigione | Funzione analeCina
-
Abbott Medical DevicesJapanese society of Congenital Interventional CardiologyReclutamentoPervietà del dotto arteriosoGiappone
-
Abbott Medical DevicesReclutamentoPFO - Forame ovale pervio | VSD - Difetto del setto ventricolare muscolare | PIVSD - Difetto del setto ventricolare muscolare post-infartuale | ASD - Difetto del setto atrialeSpagna, Germania, Polonia, Francia, Italia, Olanda, Svizzera
-
Abbott Medical DevicesAttivo, non reclutantePFO - Forame ovale pervioGiappone
-
Universitaire Ziekenhuizen KU LeuvenBytefliesCompletato
-
Abbott Medical DevicesCompletatoIctus | Fibrillazione atriale | TromboemboliaCanada, Italia, Spagna, Argentina, Belgio, Chile, Germania
-
Abbott Medical DevicesRitiratoIctus | Fibrillazione atriale | Appendice atriale sinistra
-
Abbott Medical DevicesIscrizione su invitoRigurgito aortico paravalvolareStati Uniti, Spagna, Olanda, Canada, Italia, Polonia, Regno Unito
-
Abbott Medical DevicesCompletato
-
Abbott Medical DevicesTerminatoEmicrania | Forame ovale pervio | Emicrania con aura | PFORegno Unito, Germania, Canada, Svizzera